Schedule your Pfizer COVID-19 vaccine Monday through Thursday from 8 a.m. - 5 p.m. and Friday from 8 a.m. - noon.  Learn more >

Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Investigator: Jorge Darcourt, MD

Study Coordinator:

Status: Enrolling

ClinicalTrials.gov Number: NCT03574571

Phone:

Protocol Number: Pro00022762

Description

The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone.
More to Explore
Search Clinical Trials
Join a Clinical Trial
Clinical Research Support Services for Investigators
Weill Cornell Medical College Clinical Trials